Curt Hartman: Matt, I don’t think we’re going to break out MTF again to Todd’s earlier comment. We’re not going to get into product line details every time there’s an up and a down. I would just point people to the reality that we’re in a position today to absorb some of those ups and downs. And I think that’s what the third quarter showed, that we could absorb that up and down. You’ve been around the name for a while. There’s a period in time where we couldn’t absorb that up and down. And in fact, any water that came over the side of the boat would sink us in a quarter. So I’m just thrilled with the ability of the organization to absorb those type of things, including the other supply chain challenges.
And on the growth, if you go to Slide 4 of our investor deck, there are four objectives that we lay out for shareholders. And I think this year we have achieved every one of those. And the last one on there is above market growth and leveraged earnings growth. And that’s our baseline above market growth and leveraged earnings growth. And we went back – if I go back to 2018, 2019, we said with the portfolio and our focus on innovation, there would be periods when we thought we could get into double-digit growth, and we happen to be enjoying that right now. If we dip down to 9% growth, I don’t think we’re going to be disappointed. Obviously, we’re pushing for as much growth and market capture as we can, and we’re in a very good spot right now.
So I would answer your question that way. I’m sure Todd would want to jump in here as well.
Todd Garner: Yes. Thanks, Matt. Yes, we’ve been pretty clear for a while now that we said once we anniversaried the 2022 acquisitions so In2Bones and Biorez, that we felt like we should be a double-digit organic growth company. And we’ve delivered on that this year. The one caveat that we’ve always said with that statement is that assumes a kind of normal, healthy, medtech market, right? So we’re not expecting any better than normal from a medtech market to be able to deliver that. So I would define that as kind of mid-single digit if the market is growing kind of in the mid-single digit range that we ought to be able to be a double-digit growth company. So you guys can decide what you think the market is going to do in 2024. But given a healthy, normal medtech market, as Curt said, over anything can happen in a given quarter or so. But yes, we see CONMED as a double-digit organic grower given a healthy medtech market.
Matt O’Brien: Understood. Appreciate that. And then the follow-up question, Todd, you spent a lot of time last quarter going through this on the AirSeal side of the business specifically, but the company that you are – where AirSeal is being used frequently now, is talking more vocally about getting into smoky evacuation. There’s a supplier out there that’s talking about having a valveless product. Has anything changed as far as your view of the competitive landscape in terms of having competition specifically for AirSeal being used on the intuitive robot in 2024 or 2025?
Todd Garner: Matt, let me tackle that one. I don’t think we could say any more about that topic than what we said on the second quarter call. And sitting here today, our view of the unique features and benefits, the depth of clinical validation that the marketplace has done on its own around the offering called AirSeal. We feel is uniquely positioned in the marketplace today. And we don’t currently see anything pending to enter the marketplace that we believe would disrupt our position. And in addition, we would just remind everybody that while robotics is an important part of that market, 10x the size is the general laparoscopic market. And we have very good and growing representation in the general laparoscopic market. And in both cases, whether it’s in robotics or in laparoscopic, we’re replacing standard insufflation, and we feel really good about our offering.
